KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.

Julien Ognard, Sevda Alipour Khabir, Sherief Ghozy, Gerard El Hajj, Kevin M Kallmes, John J Chen, Ramanathan Kadirvel, David F Kallmes, Waleed Brinjikji

J Headache Pain 26(1) 202

PMID41057780
PMCIDPMC12502165
DOI10.1186/s10194-025-02148-3
发表日期2025-10-07
摘要

摘要

BACKGROUND: Idiopathic intracranial hypertension (IIH) is a debilitating neurologic condition marked by elevated intracranial pressure (ICP), typically affecting obese women of reproductive age. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for obesity and diabetes, have recently emerged as potential therapeutic agents for IIH. OBJECTIVE: To systematically evaluate the efficacy and safety of GLP-1 RAs in IIH, based on clinical studies reporting outcomes related to ICP, headache, vision, cognition, weight loss, and safety. METHODS: A systematic search was conducted across MEDLINE, Scopus, and Web of Science up to June 15, 2025, using PRISMA 2020 guidelines. Studies involving adult IIH patients treated with GLP-1 RAs and reporting relevant clinical outcomes were included. Data extraction and bias assessment were performed independently by multiple reviewers. RESULTS: Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included. GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions. In a small RCT, exenatide significantly lowered ICP within hours of administration. Several studies reported papilledema resolution and a lower risk of visual deterioration. Cognitive function either improved or remained stable. Adverse effects were mostly mild gastrointestinal symptoms; no serious safety concerns emerged. Interpretation is limited by the predominance of potentially overlapped retrospective data and minimal randomized evidence. CONCLUSION: GLP-1 RAs show promise as a disease-modifying therapy for IIH, with potential benefits beyond weight loss. The consistency of findings across multiple studies and data sources provides justification of a shift in research focus to conduct well-powered phase 3 randomized controlled trials to validate these preliminary findings and define optimal treatment strategies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。